Role of angiotensin-converting enzyme and vitamin D receptor gene polymorphisms in cancer anorexia-cachexia syndrome

American Journal of Immunology

Volumn 8, Issue 3, 2012, Pages 65-70

  Fabris, Ariele ^a   Biagioni, Paolo ^b   Punzi, Tiziana ^c   Morucci, Gabriele ^c   Gulisano, Massimo ^c   Pacini, Stefania ^c   Ruggiero, Marco ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MISERICORDIA E DOLCE HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Inflammation; Prognosis; Weight loss

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; VITAMIN D RECEPTOR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; CACHEXIA; CANCER ANOREXIA CACHEXIA SYNDROME; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; DNA POLYMORPHISM; FEMALE; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; INDEL MUTATION; LIFE EXPECTANCY; MALE; MALNUTRITION; NUTRITIONAL STATUS; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84868376739     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2012.65.70     Document Type: Article

References (19)

1. AIOM, 2008. Trattamento e prevenzione della cachessia neoplastica. Associazione Italiana Oncologia Medica, Italia.
2. Bennani-Baiti, N. and D. Walsh, 2009. What is cancer anorexia-cachexia syndrome? A historical perspective. J. R. Coll. Physicians Edinb., 39: 257-262. PMID: 20608345
3. Camps, C., V. Iranzo, R.M. Bremnes and R. Sirera, 2006. Anorexia-cachexia syndrome in cancer: Implications of the ubiquitin-proteasome pathway. Support Care Cancer, 14: 1173-1183. PMID: 16819628
4. Delafontaine, P. and M. Akao, 2006. Angiotensin II as candidate of cardiac cachexia. Curr. Opin. Clin. Nutr. Metab. Care, 9: 220-224. PMID: 16607120
5. Harrison, T.R., 1998. Principles of Internal Medicine. 13th Edn., McGraw Hill, New York, ISBN-10: 0070645183, pp: 510.
6. Jurutka, P., G. Whitfield, J.C. Hsieh, P.D. Thompson and C.A. Haussler et al., 2001. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev. Endocr. Metab. Disord., 2: 203-216. PMID: 11705326
7. Khatami, M., 2011. Unresolved inflammation: Immune tsunami" or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer. Expert. Opin. Biol. Ther., 11: 1419-1432. PMID: 21663532
8. MacDonald, N., 2011. Chronic inflammatory states: Their relationship to cancer prognosis and symptoms. J.R. Coll. Physicians Edinb., 41: 246-253. PMID: 21949925
9. Mahmoud, F.A. and N.I. Rivera, 2002. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr. Oncol. Rep., 4: 250-255. PMID: 11937016
10. Moore, D., S. Kato, W. Xie, D.J. Mangelsdorf and D. R. Schmidt et al., 2006. International union of pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta and vitamin D receptor. Pharmacol. Rev., 58: 742-759. PMID: 17132852
11. Nelson, K.A. and D. Walsh, 2002. The cancer anorexia-cachexia syndrome: A survey of the Prognostic Inflammatory and Nutritional Index (PINI) in advanced disease. J. Pain Symptom Manage., 24: 424-428. PMID: 12505211
12. Ortiz, R.M., H. Kobori, D. Conte and L.G. Navar, 2010. Angiotensin II-induced reduction in body mass is Ang II receptor mediated in association with elevated corticosterone. Growth Horm. IGF Res., 20: 282-288. PMID: 20483644
13. Punzi, T., A. Fabris, G. Morucci, P. Biagioni and M. Gulisano et al., 2012. C-reactive protein levels and vitamin D receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol. Diagn. Ther., 16: 115-124. PMID: 22497530
14. Ruggiero, M. and S. Pacini, 2011. The vitamin D axis in chronic kidney disease-State of the art and future perspectives. Europ. Nephrol., 5: 15-19.
15. Sanders, P.M., S.T. Russell and M.J. Tisdale, 2005. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Brit. J. Cancer, 93: 425-434. PMID: 16052213
16. Stitt, T., D. Drujan, B. Clarke, F. Panaro and Y. Timofeyva et al., 2004. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell., 14: 395-403. PMID: 15125842
17. Ströhle, A., K. Zänker and A. Hahn, 2010. Nutrition in oncology: The case of micronutrients (review). Oncol. Rep., 24: 815-828. PMID: 20811659
18. Vigano, A.A., N. Hamel, J. Morais, W. Foulkes and R. Kilgour et al., 2007. Angiotensin-converting enzyme gene polymorphism (ACEGP) and Cancer Cachexia (CC): Is there a link? J. Clinical Oncol.
19. Yates, J.W., B. Chalmar and F.P. Mc Kegney, 1980. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer, 45: 2220-2224. PMID: 7370963